Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2–3 randomised trial
Date
2018-03
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Adams, R, Brown, E, Brown, L, Butler, R, Falk, S, Fisher, D, Kaplan, R, Quirke, P, Richman, S, Samuel, L, Seligman, J, Seymour, M, Shui, K K, Wasan, H, Wilson, R & Maughan, T 2018, 'Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D) : a phase 2–3 randomised trial', The Lancet Gastroenterology & Hepatology, vol. 3, no. 3, pp. 162–171. https://doi.org/10.1016/S2468-1253(17)30394-1